SHILPAMED943.00

Shilpa Medicare Ltd.

· Pharma & Health
₹ CrorePeersNATCOPHARMSPARCSTARRUBICONSUPRIYATHYROCAREVIYASHPARKHOSPSMcap ₹18,445 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation107.9113.0119.7
+ Impairment Loss / (Reversal)0.01.00.0
+ Finance Costs91.875.547.7
+ Interest Income-1.4-8.0-0.7
+ Fair Value (Gains) / Losses0.0-0.10.0
+ Unrealised FX (Gain) / Loss-0.9-4.3-28.5
+ Other Non-cash Items3.6-21.74.2
Changes in Working Capital
+ Inventories-25.1-22.3-37.0
+ Trade Receivables — Current-75.9-55.4-66.5
+ Other Current Assets-10.40.04.8
+ Other Non-current Assets0.0-45.00.0
+ Trade Payables — Current34.3-69.434.7
+ Other Financial Liabilities — Current0.054.50.0
+ Other Current Liabilities0.00.028.9
+ Other Non-current Liabilities-6.654.50.0
Cash from Operating Activities
Profit Before Tax (per I/S)59.1123.6295.3338.3
+ Total Adjustments (incl. Working Capital)117.472.3107.3
Cash from Operations (pre-tax)176.5195.9402.6
+ Other Inflows / (Outflows) — Operating0.0-16.70.0
+ Income Taxes Paid41.247.060.4
Cash from Operating Activities135.3132.2342.2
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)184.6243.6370.6
+ Disp of Fixed Assets12.10.00.0
+ Disp of Investment Property0.027.50.0
+ Disp of Other Long-term Assets0.00.013.3
+ Purchase of Investments (Equity / Debt)0.00.018.9
+ Sale of Investments (Equity / Debt)0.00.049.7
+ Disp of Interests in Joint Ventures0.08.10.0
+ Disp of Subsidiaries / Businesses (net)11.00.00.0
+ Interest Received — Investing1.48.10.7
+ Other Inflows / (Outflows) — Investing-6.50.90.0
Cash from Investing Activities-166.6-199.1-325.9
Cash from Financing Activities
+ Proceeds from Issue of Shares0.0489.10.0
+ Proceeds from Borrowings139.7-349.2104.8
+ Repayment of Borrowings0.00.033.2
+ Payment of Lease Liabilities0.50.60.6
+ Interest Paid92.476.747.6
+ Dividends Paid0.00.09.8
Cash from Financing Activities46.862.713.6
Net Changes in Cash (pre-FX)15.5-4.329.9
+ Effect of FX Rate Changes on Cash-4.20.0-13.3
Net Changes in Cash11.4-4.316.6
Closing Cash30.4
Reference Items
EBITDA244.5317.0434.7478.6
EBITDA Margin %21.2324.6528.2528.44
Free Cash Flow (CFO − Capex)-49.2-111.5-28.5-28.5
Free Cash Flow to Equity-537.4-4.4
Free Cash Flow per Basic Share-2.52-5.70-1.45-1.45
Cash Flow to Net Income4.251.691.41
Cash Paid for Taxes41.247.060.4
Cash Paid for Interest92.476.747.6
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.